{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T21:15:18Z","timestamp":1782940518460,"version":"3.54.5"},"reference-count":71,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"am","delay-in-days":347,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NS028840"],"award-info":[{"award-number":["NS028840"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NS115438"],"award-info":[{"award-number":["NS115438"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NS12082"],"award-info":[{"award-number":["NS12082"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R33 NS112407"],"award-info":[{"award-number":["R33 NS112407"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-19-1-0816"],"award-info":[{"award-number":["W81XWH-19-1-0816"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Clinics of North America"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.pcl.2023.05.007","type":"journal-article","created":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T20:45:03Z","timestamp":1694465103000},"page":"937-950","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Shedding New Light"],"prefix":"10.1016","volume":"70","author":[{"given":"Natasha","family":"Pillay-Smiley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan S.","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"de Blank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Ratner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.pcl.2023.05.007_bib1","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1038\/gim.2017.215","article-title":"Prevalence of neurofibromatosis type 1 in the Finnish population","volume":"20","author":"Kallionpaa","year":"2018","journal-title":"Genet Med"},{"issue":"2","key":"10.1016\/j.pcl.2023.05.007_bib2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00439-021-02410-z","article-title":"Challenges in the diagnosis of neurofibromatosis type 1 (NF1) in young children facilitated by means of revised diagnostic criteria including genetic testing for pathogenic NF1 gene variants","volume":"141","author":"Kehrer-Sawatzki","year":"2022","journal-title":"Hum Genet"},{"issue":"8","key":"10.1016\/j.pcl.2023.05.007_bib3","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1038\/s41436-021-01170-5","article-title":"Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation","volume":"23","author":"Legius","year":"2021","journal-title":"Genet Med"},{"issue":"4","key":"10.1016\/j.pcl.2023.05.007_bib4","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1212\/WNL.48.4.1121","article-title":"Cognitive function and academic performance in neurofibromatosis. 1: consensus statement from the NF1 Cognitive Disorders Task Force","volume":"48","author":"North","year":"1997","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.pcl.2023.05.007_bib5","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1172\/JCI41443","article-title":"Genetic and cellular evidence of vascular inflammation in neurofibromin-deficient mice and humans","volume":"120","author":"Lasater","year":"2010","journal-title":"J\u00a0Clin Invest"},{"issue":"11","key":"10.1016\/j.pcl.2023.05.007_bib6","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1002\/humu.22392","article-title":"NF1 molecular characterization and neurofibromatosis type I genotype-phenotype correlation: the French experience","volume":"34","author":"Sabbagh","year":"2013","journal-title":"Hum Mutat"},{"issue":"19","key":"10.1016\/j.pcl.2023.05.007_bib7","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1001\/jama.2009.1663","article-title":"Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome","volume":"302","author":"Messiaen","year":"2009","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.pcl.2023.05.007_bib8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/gcc.22997","article-title":"Recurrent NF1 gene variants and their genotype\/phenotype correlations in patients with neurofibromatosis type I","volume":"61","author":"Riva","year":"2022","journal-title":"Genes Chromosomes Cancer"},{"issue":"5","key":"10.1016\/j.pcl.2023.05.007_bib9","doi-asserted-by":"crossref","first-page":"e0216527","DOI":"10.1371\/journal.pone.0216527","article-title":"The evolution and multi-molecular properties of NF1 cutaneous neurofibromas originating from C-fiber sensory endings and terminal Schwann cells at normal sites of sensory terminations in the skin","volume":"14","author":"Rice","year":"2019","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.pcl.2023.05.007_bib10","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/90148","article-title":"Mitotic recombination effects homozygosity for NF1 germline mutations in neurofibromas","volume":"28","author":"Serra","year":"2001","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.pcl.2023.05.007_bib11","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00401-021-02276-5","article-title":"Integrated molecular and clinical analysis of low-grade gliomas in children with neurofibromatosis type 1 (NF1)","volume":"141","author":"Fisher","year":"2021","journal-title":"Acta Neuropathol"},{"issue":"6","key":"10.1016\/j.pcl.2023.05.007_bib12","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1093\/neuonc\/noaa036","article-title":"Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference","volume":"22","author":"Packer","year":"2020","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.pcl.2023.05.007_bib13","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1101\/gr.142604.112","article-title":"Somatic neurofibromatosis type 1 (NF1) inactivation characterizes NF1-associated pilocytic astrocytoma","volume":"23","author":"Gutmann","year":"2013","journal-title":"Genome Res"},{"issue":"9","key":"10.1016\/j.pcl.2023.05.007_bib14","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1212\/01.wnl.0000250332.89420.e6","article-title":"NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight","volume":"68","author":"Dombi","year":"2007","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.pcl.2023.05.007_bib15","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/(SICI)1098-2264(199903)24:3<283::AID-GCC15>3.0.CO;2-K","article-title":"Loss of NF1 allele in Schwann cells but not in fibroblasts derived from an NF1-associated neurofibroma","volume":"24","author":"Kluwe","year":"1999","journal-title":"Genes Chromosomes Cancer"},{"issue":"7","key":"10.1016\/j.pcl.2023.05.007_bib16","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1158\/1541-7786.MCR-19-0147","article-title":"Malignant peripheral nerve sheath tumors: from epigenome to bedside","volume":"17","author":"Korfhage","year":"2019","journal-title":"Mol Cancer Res"},{"issue":"1","key":"10.1016\/j.pcl.2023.05.007_bib17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40364-021-00281-0","article-title":"MEK inhibitors: novel targeted therapies of neurofibromatosis associated benign and malignant lesions","volume":"9","author":"Harder","year":"2021","journal-title":"Biomark Res"},{"issue":"3","key":"10.1016\/j.pcl.2023.05.007_bib18","doi-asserted-by":"crossref","first-page":"e210945","DOI":"10.1001\/jamanetworkopen.2021.0945","article-title":"Comparison of cancer prevalence in patients with neurofibromatosis type 1 at an academic cancer center vs in the general population from 1985 to 2020","volume":"4","author":"Landry","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"11","key":"10.1016\/j.pcl.2023.05.007_bib19","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1002\/ijc.32187","article-title":"Pediatric malignancies in neurofibromatosis type 1: a population-based cohort study","volume":"145","author":"Peltonen","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.pcl.2023.05.007_bib20","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/bs.acr.2021.07.007","article-title":"The RASopathies: biology, genetics and therapeutic options","volume":"153","author":"Longo","year":"2022","journal-title":"Adv Cancer Res"},{"issue":"3","key":"10.1016\/j.pcl.2023.05.007_bib21","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.gde.2009.04.001","article-title":"The RASopathies: developmental syndromes of Ras\/MAPK pathway dysregulation","volume":"19","author":"Tidyman","year":"2009","journal-title":"Curr Opin Genet Dev"},{"issue":"5","key":"10.1016\/j.pcl.2023.05.007_bib22","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.cell.2007.05.018","article-title":"GEFs and GAPs: critical elements in the control of small G proteins","volume":"129","author":"Bos","year":"2007","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.pcl.2023.05.007_bib23","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/sj.leu.2402945","article-title":"Signal transduction mediated by the Ras\/Raf\/MEK\/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention","volume":"17","author":"Chang","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.pcl.2023.05.007_bib24","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/978-1-60761-795-2_8","article-title":"Activation of Ras and Rho GTPases and MAP kinases by G-protein-coupled receptors","volume":"661","author":"Chiariello","year":"2010","journal-title":"Methods Mol Biol"},{"issue":"1","key":"10.1016\/j.pcl.2023.05.007_bib25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS proteins and their regulators in human disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.pcl.2023.05.007_bib26","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nri3495","article-title":"Mitogen-activated protein kinases in innate immunity","volume":"13","author":"Arthur","year":"2013","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"10.1016\/j.pcl.2023.05.007_bib27","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1038\/ng2113","article-title":"Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype","volume":"39","author":"Brems","year":"2007","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.pcl.2023.05.007_bib28","doi-asserted-by":"crossref","first-page":"107909","DOI":"10.1016\/j.celrep.2020.107909","article-title":"Structural insights into the SPRED1-neurofibromin-KRAS complex and disruption of SPRED1-neurofibromin interaction by oncogenic EGFR","volume":"32","author":"Yan","year":"2020","journal-title":"Cell Rep"},{"issue":"12","key":"10.1016\/j.pcl.2023.05.007_bib29","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/s41594-021-00687-2","article-title":"The cryo-EM structure of the human neurofibromin dimer reveals the molecular basis for neurofibromatosis type 1","volume":"28","author":"Lupton","year":"2021","journal-title":"Nat Struct Mol Biol"},{"issue":"7884","key":"10.1016\/j.pcl.2023.05.007_bib30","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41586-021-04024-x","article-title":"The structure of neurofibromin isoform 2 reveals different functional states","volume":"599","author":"Naschberger","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.pcl.2023.05.007_bib31","series-title":"Neurofibromatosis type 1: Molecular and cellular biology","first-page":"305","article-title":"Neurofibromin: protein domains and functional characteristics","author":"Scheffzek","year":"2012"},{"issue":"5447","key":"10.1016\/j.pcl.2023.05.007_bib32","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1126\/science.286.5447.2172","article-title":"Mouse models of tumor development in neurofibromatosis type 1","volume":"286","author":"Cichowski","year":"1999","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.pcl.2023.05.007_bib33","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/ng0794-353","article-title":"Tumour predisposition in mice heterozygous for a targeted mutation in Nf1","volume":"7","author":"Jacks","year":"1994","journal-title":"Nat Genet"},{"issue":"5569","key":"10.1016\/j.pcl.2023.05.007_bib34","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1126\/science.1068452","article-title":"Neurofibromas in NF1: Schwann cell origin and role of tumor environment","volume":"296","author":"Zhu","year":"2002","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.pcl.2023.05.007_bib35","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ccr.2007.12.027","article-title":"Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells","volume":"13","author":"Wu","year":"2008","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.pcl.2023.05.007_bib36","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1158\/2159-8290.CD-18-0151","article-title":"Spatiotemporal loss of NF1 in Schwann cell lineage leads to different types of cutaneous neurofibroma susceptible to modification by the Hippo pathway","volume":"9","author":"Chen","year":"2019","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.pcl.2023.05.007_bib37","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1158\/2159-8290.CD-18-0156","article-title":"Cellular origin, tumor progression, and pathogenic mechanisms of cutaneous neurofibromas revealed by mice with Nf1 knockout in boundary cap cells","volume":"9","author":"Radomska","year":"2019","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.pcl.2023.05.007_bib38","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00401-012-1056-7","article-title":"Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition","volume":"125","author":"Prada","year":"2013","journal-title":"Acta Neuropathol"},{"issue":"1","key":"10.1016\/j.pcl.2023.05.007_bib39","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.celrep.2013.08.033","article-title":"Injury signals cooperate with Nf1 loss to relieve the tumor-suppressive environment of adult peripheral nerve","volume":"5","author":"Ribeiro","year":"2013","journal-title":"Cell Rep"},{"issue":"18","key":"10.1016\/j.pcl.2023.05.007_bib40","doi-asserted-by":"crossref","first-page":"e154513","DOI":"10.1172\/jci.insight.154513","article-title":"Multiple Nf1 Schwann cell populations reprogram the plexiform neurofibroma tumor microenvironment","volume":"7","author":"Kershner","year":"2022","journal-title":"JCI Insight"},{"issue":"5","key":"10.1016\/j.pcl.2023.05.007_bib41","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/neuonc\/nou004","article-title":"Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas","volume":"16","author":"Widemann","year":"2014","journal-title":"Neuro Oncol"},{"issue":"21 Suppl 1","key":"10.1016\/j.pcl.2023.05.007_bib42","first-page":"S33","article-title":"Recommendations for imaging tumor response in neurofibromatosis clinical trials","volume":"81","author":"Dombi","year":"2013","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.pcl.2023.05.007_bib43","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/pbc.23015","article-title":"Preclincial testing of sorafenib and RAD001 in the Nf(flox\/flox); DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging","volume":"58","author":"Wu","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"26","key":"10.1016\/j.pcl.2023.05.007_bib44","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","article-title":"Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas","volume":"375","author":"Dombi","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.pcl.2023.05.007_bib45","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1172\/JCI60578","article-title":"MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors","volume":"123","author":"Jessen","year":"2013","journal-title":"J\u00a0Clin Invest"},{"issue":"10","key":"10.1016\/j.pcl.2023.05.007_bib46","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1002\/pbc.25546","article-title":"Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of neurofibromatosis type 1","volume":"62","author":"Jousma","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"10.1016\/j.pcl.2023.05.007_bib47","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/S1470-2045(12)70414-X","article-title":"Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial","volume":"13","author":"Robertson","year":"2012","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1016\/j.pcl.2023.05.007_bib48","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1158\/1078-0432.CCR-20-5032","article-title":"FDA approval summary: selumetinib for plexiform neurofibroma","volume":"27","author":"Casey","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"15","key":"10.1016\/j.pcl.2023.05.007_bib49","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in children with inoperable plexiform neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.pcl.2023.05.007_bib50","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1200\/JCO.20.02220","article-title":"NF106: a Neurofibromatosis Clinical Trials Consortium phase II trial of the MEK inhibitor mirdametinib (PD-0325901) in adolescents and adults with NF1-related plexiform neurofibromas","volume":"39","author":"Weiss","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.pcl.2023.05.007_bib51","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41591-020-01193-6","article-title":"Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial","volume":"27","author":"Fisher","year":"2021","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.pcl.2023.05.007_bib52","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(19)30277-3","article-title":"Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial","volume":"20","author":"Fangusaro","year":"2019","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.pcl.2023.05.007_bib53","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1038\/ng.3400","article-title":"The genomic landscape of juvenile myelomonocytic leukemia","volume":"47","author":"Stieglitz","year":"2015","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.pcl.2023.05.007_bib54","first-page":"1","article-title":"Juvenile myelomonocytic leukemia: a comprehensive review and recent advances in management","volume":"11","author":"Gupta","year":"2021","journal-title":"Am J Blood Res"},{"issue":"76","key":"10.1016\/j.pcl.2023.05.007_bib55","doi-asserted-by":"crossref","first-page":"76ra27","DOI":"10.1126\/scitranslmed.3001069","article-title":"A\u00a0MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice","volume":"3","author":"Lyubynska","year":"2011","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.pcl.2023.05.007_bib56","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/neuonc\/nos287","article-title":"Survival meta-analyses for\u00a0>1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1","volume":"15","author":"Kolberg","year":"2013","journal-title":"Neuro Oncol"},{"issue":"11","key":"10.1016\/j.pcl.2023.05.007_bib57","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1038\/s41436-020-0885-3","article-title":"A\u00a0molecular basis for neurofibroma-associated skeletal manifestations in NF1","volume":"22","author":"Ma","year":"2020","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.pcl.2023.05.007_bib58","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1097\/BPO.0000000000001650","article-title":"Are some randomized clinical trials impossible?","volume":"41","author":"Rios","year":"2021","journal-title":"J\u00a0Pediatr Orthop"},{"issue":"7","key":"10.1016\/j.pcl.2023.05.007_bib59","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1212\/01.wnl.0000179303.72345.ce","article-title":"The nature and frequency of cognitive deficits in children with neurofibromatosis type 1","volume":"65","author":"Hyman","year":"2005","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.pcl.2023.05.007_bib60","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1586\/14737175.2014.953931","article-title":"Cognitive and behavioral problems in children with neurofibromatosis type 1: challenges and future directions","volume":"14","author":"Schwetye","year":"2014","journal-title":"Expert Rev Neurother"},{"issue":"5","key":"10.1016\/j.pcl.2023.05.007_bib61","doi-asserted-by":"crossref","first-page":"e616","DOI":"10.1212\/NXG.0000000000000616","article-title":"Impact of MEK inhibitor therapy on neurocognitive functioning in NF1","volume":"7","author":"Walsh","year":"2021","journal-title":"Neurol Genet"},{"key":"10.1016\/j.pcl.2023.05.007_bib62","series-title":"Impact of trametinib on the neuropsychological profile of NF1 patients","author":"Lalancette","year":"2022"},{"issue":"11","key":"10.1016\/j.pcl.2023.05.007_bib63","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1093\/neuonc\/noac165","article-title":"MEK inhibitors for neurofibromatosis type 1 manifestations: clinical evidence and consensus","volume":"24","author":"de Blank","year":"2022","journal-title":"Neuro Oncol"},{"issue":"4","key":"10.1016\/j.pcl.2023.05.007_bib64","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jos.2020.05.016","article-title":"Modulation of spine fusion with BMP-2, MEK inhibitor (PD0325901), and zoledronic acid in a murine model of NF1 double inactivation","volume":"26","author":"Bobyn","year":"2021","journal-title":"J\u00a0Orthop Sci"},{"issue":"7","key":"10.1016\/j.pcl.2023.05.007_bib65","doi-asserted-by":"crossref","first-page":"e1109","DOI":"10.1634\/theoncologist.2020-0069","article-title":"The use of MEK inhibitors in neurofibromatosis type 1-associated tumors and management of toxicities","volume":"25","author":"Klesse","year":"2020","journal-title":"Oncol"},{"issue":"8","key":"10.1016\/j.pcl.2023.05.007_bib66","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/humu.20748","article-title":"The RAS\/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders","volume":"29","author":"Aoki","year":"2008","journal-title":"Hum Mutat"},{"issue":"11","key":"10.1016\/j.pcl.2023.05.007_bib67","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.3324\/haematol.2014.114595","article-title":"RAS diseases in children","volume":"99","author":"Niemeyer","year":"2014","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.pcl.2023.05.007_bib68","doi-asserted-by":"crossref","first-page":"e20200167","DOI":"10.1542\/peds.2020-0167","article-title":"Severe lymphatic disorder resolved with MEK inhibition in a patient with Noonan syndrome and SOS1 mutation","volume":"146","author":"Dori","year":"2020","journal-title":"Pediatrics"},{"key":"10.1016\/j.pcl.2023.05.007_bib69","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jpeds.2022.05.030","article-title":"Trametinib for refractory chylous effusions and systemic complications in children with Noonan syndrome","volume":"248","author":"Nakano","year":"2022","journal-title":"J\u00a0Pediatr"},{"issue":"17","key":"10.1016\/j.pcl.2023.05.007_bib70","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.jacc.2019.01.066","article-title":"Hypertrophic cardiomyopathy in Noonan syndrome treated by MEK-inhibition","volume":"73","author":"Andelfinger","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.pcl.2023.05.007_bib71","doi-asserted-by":"crossref","first-page":"104630","DOI":"10.1016\/j.ejmg.2022.104630","article-title":"Successful MEK-inhibition of severe hypertrophic cardiomyopathy in RIT1-related Noonan syndrome","volume":"65","author":"Leegaard","year":"2022","journal-title":"Eur J Med Genet"}],"container-title":["Pediatric Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031395523000986?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031395523000986?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T17:26:45Z","timestamp":1758475605000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031395523000986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":71,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0031395523000986"],"URL":"https:\/\/doi.org\/10.1016\/j.pcl.2023.05.007","relation":{},"ISSN":["0031-3955"],"issn-type":[{"value":"0031-3955","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Shedding New Light","name":"articletitle","label":"Article Title"},{"value":"Pediatric Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcl.2023.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}